Weekly Analysts’ Ratings Updates for Tandem Diabetes Care (TNDM)

A number of firms have modified their ratings and price targets on shares of Tandem Diabetes Care (NASDAQ: TNDM) recently:

• 8/7/2026 – Tandem Diabetes Care had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $26.00 price target on the stock, down from $30.00.
• 8/7/2026 – Tandem Diabetes Care was given a new $40.00 price target by Canaccord Genuity Group Inc..
• 8/7/2026 – Tandem Diabetes Care had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $21.00 price target on the stock, up from $17.00.
• 8/7/2026 – Tandem Diabetes Care had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 7/28/2026 – Tandem Diabetes Care is now covered by UBS Group AG. They set a “neutral” rating and a $18.00 price target on the stock.
• 7/15/2026 – Tandem Diabetes Care had its price target lowered by Mizuho from $24.00 to $20.00. They now have a “neutral” rating on the stock.
• 6/23/2026 – Tandem Diabetes Care is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $15.50 price target on the stock.

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.